Abstract:Key Teaching Points•Since genetic testing for long QT syndrome exerts a substantial diagnostic, prognostic, and therapeutic impact for the index cases and their affected family members, it is of critical importance to identify the exact disease-causing mutation and to properly rule out benign variants.•The article contains a fundamentally important message and dispels a commonly held perception, namely, that identification of a rare variant does not automatically equate to a disease diagnosis.•Even KCNQ1 mutations within areas of high probability of pathogenicity (ie, transmembrane spanning or pore-forming regions) or indicated by a genetic test company as “deleterious” should be interpreted with caution, especially if the variant-positive individuals have insufficient clinical evidence for a diagnosis of long QT syndrome in the first place.•It is important that physicians analyze the veracity and concordance of the evidence underpinning both the alleged genotype and the alleged phenotype. If discordance exists, one must be critical of any genetic test company's interpretation and tread carefully with the use of the genotypic data in their clinical decision making.•Genetic testing continues to be perceived as the ultimate diagnostic arbiter, yet the perils of testing in a poorly phenotyped family can be significant as illustrated in this case, with major implications for the family in terms of medical care, potential restrictions, insurance, and the psychological burden such a diagnosis brings. •Since genetic testing for long QT syndrome exerts a substantial diagnostic, prognostic, and therapeutic impact for the index cases and their affected family members, it is of critical importance to identify the exact disease-causing mutation and to properly rule out benign variants.•The article contains a fundamentally important message and dispels a commonly held perception, namely, that identification of a rare variant does not automatically equate to a disease diagnosis.•Even KCNQ1 mutations within areas of high probability of pathogenicity (ie, transmembrane spanning or pore-forming regions) or indicated by a genetic test company as “deleterious” should be interpreted with caution, especially if the variant-positive individuals have insufficient clinical evidence for a diagnosis of long QT syndrome in the first place.•It is important that physicians analyze the veracity and concordance of the evidence underpinning both the alleged genotype and the alleged phenotype. If discordance exists, one must be critical of any genetic test company's interpretation and tread carefully with the use of the genotypic data in their clinical decision making.•Genetic testing continues to be perceived as the ultimate diagnostic arbiter, yet the perils of testing in a poorly phenotyped family can be significant as illustrated in this case, with major implications for the family in terms of medical care, potential restrictions, insurance, and the psychological burden such a diagnosis brings.

Long QT Syndrome Type 5-Lite: Defining the Clinical Phenotype Associated with the Potentially Proarrhythmic P.asp85asn-Kcne1 Common Genetic Variant.

Clinical and functional reappraisal of alleged type 5 long QT syndrome: Causative genetic variants in the KCNE1-encoded minK β-subunit.

Clinical Aspects of Type-1 Long-Qt Syndrome by Location, Coding Type, and Biophysical Function of Mutations Involving the KCNQ1 Gene.

Risk of syncope in family members who are genotype-negative for a family-associated long-QT syndrome mutation.

Location of mutation in the KCNQ1 and phenotypic presentation of long QT syndrome.

Mutations in conserved amino acids in the KCNQ1 channel and risk of cardiac events in type-1 long-QT syndrome.

Risk for Life-Threatening Cardiac Events in Patients with Genotype-Confirmed Long-Qt Syndrome and Normal-Range Corrected QT Intervals.

Novel Compound Heterozygous Mutations in the KCNQ1 Gene Associated with Autosomal Recessive Long QT Syndrome (jervell and Lange‐Nielsen Syndrome)

A Phenotype-Enhanced Variant Classification Framework to Decrease the Burden of Missense Variants of Uncertain Significance in Type 1 Long QT Syndrome

Mutation-Specific Risk in Two Genetic Forms of Type 3 Long QT Syndrome

Genetic characterization of KCNQ1 variants improves risk stratification in type 1 long QT syndrome patients

Even Pore-Localizing Missense Variants at Highly Conserved Sites in KCNQ1-encoded Kv7.1 Channels May Have Wild-Type Function and Not Cause Type 1 Long QT Syndrome: Do Not Rely Solely on the Genetic Test Company's Interpretation.

Prognostic Implications of Mutation-Specific QTc Standard Deviation in Congenital Long QT Syndrome.

Α-1-syntrophin Mutation and the Long-QT Syndrome

Lqts Gene Lovd Database

Exploring the impact of a KCNH2 missense variant on Long QT syndrome: insights into a novel gender-selective, incomplete penetrance inheritance mode

PO-630-04 ELUCIDATION OF ALG10B AS A NOVEL LONG QT SYNDROME SUSCEPTIBILITY GENE

Variable Clinical Appearance of the Kir2.1 Rare Variants in Russian Patients with Long QT Syndrome

Clinical Course And Risk Stratification Of Patients Affected With The Jervell And Lange-Nielsen Syndrome

Mutations In Cytoplasmic Loops Of The Kcnq1 Channel And The Risk Of Life-Threatening Events Implications For Mutation-Specific Response To Beta-Blocker Therapy In Type 1 Long-Qt Syndrome

Mutations in Cytoplasmic Loops of the KCNQ1 Channel and the Risk of Life-Threatening Events